{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:19:55Z","timestamp":1776889195446,"version":"3.51.2"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["slas-discovery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Discovery"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.slasd.2025.100230","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:29:07Z","timestamp":1744165747000},"page":"100230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroids"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3896-7909","authenticated-orcid":false,"given":"Nathan P.","family":"Coussens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6444-3121","authenticated-orcid":false,"given":"Thomas S.","family":"Dexheimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Silvers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6354-0368","authenticated-orcid":false,"given":"Phillip R.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7973-5912","authenticated-orcid":false,"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda G.","family":"Hollingshead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-4954","authenticated-orcid":false,"given":"Naoko","family":"Takebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly A.","family":"Teicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.slasd.2025.100230_bib0001","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/2159-8290.CD-20-0789","article-title":"Modes of regulated cell death in cancer","volume":"11","author":"Koren","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.slasd.2025.100230_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174363","article-title":"Apoptosis deregulation and the development of cancer multi-drug resistance","volume":"13","author":"Neophytou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.slasd.2025.100230_bib0003","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.slasd.2025.100230_bib0004","doi-asserted-by":"crossref","first-page":"205","DOI":"10.15171\/apb.2019.024","article-title":"Understanding apoptosis and apoptotic pathways targeted cancer therapeutics","volume":"9","author":"Jan","year":"2019","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.slasd.2025.100230_bib0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.slasd.2025.100230_bib0006","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","article-title":"The multiple mechanisms that regulate p53 activity and cell fate","volume":"20","author":"Hafner","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.slasd.2025.100230_bib0007","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.slasd.2025.100230_bib0008","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cell.2014.03.004","article-title":"Coming full circle-from endless complexity to simplicity and back again","volume":"157","author":"Weinberg","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.slasd.2025.100230_bib0009","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05541","article-title":"Restoration of p53 function leads to tumour regression in vivo","volume":"445","author":"Ventura","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.slasd.2025.100230_bib0010","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature05529","article-title":"Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas","volume":"445","author":"Xue","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.slasd.2025.100230_bib0011","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1021\/acs.jmedchem.6b01665","volume":"60","author":"Aguilar","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.slasd.2025.100230_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/ptr.8157","article-title":"Comprehensive review of bcl-2 family proteins in cancer apoptosis: therapeutic strategies and promising updates of natural bioactive compounds and small molecules","author":"Iksen","year":"2024","journal-title":"Phytother Res"},{"key":"10.1016\/j.slasd.2025.100230_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188569","article-title":"Targeting Bcl-2 for cancer therapy","volume":"1876","author":"Zhang","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.slasd.2025.100230_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114184","article-title":"Trends in targeting bcl-2 anti-apoptotic proteins for cancer treatment","volume":"232","author":"Zhang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.slasd.2025.100230_bib0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 protein family: attractive targets for cancer therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis"},{"key":"10.1016\/j.slasd.2025.100230_bib0016","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.180002","article-title":"Targeting BCL-2 regulated apoptosis in cancer","volume":"8","author":"Campbell","year":"2018","journal-title":"Open Biol"},{"key":"10.1016\/j.slasd.2025.100230_bib0017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.slasd.2025.100230_bib0018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.slasd.2025.100230_bib0019","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0959-8049(14)70464-2","article-title":"BM-1252 (APG-1252): a potent dual specific bcl-2\/bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity","volume":"50","author":"Bai","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.slasd.2025.100230_bib0020","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","article-title":"Bcl-2 family proteins are essential for platelet survival","volume":"14","author":"Zhang","year":"2007","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.slasd.2025.100230_bib0021","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.slasd.2025.100230_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071671","article-title":"A review of the current impact of inhibitors of apoptosis proteins and their repression in cancer","volume":"14","author":"Cetraro","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.slasd.2025.100230_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107610","article-title":"The multiple roles of the IAP super-family in cancer","volume":"214","author":"Kumar","year":"2020","journal-title":"Pharmacol Therapeut"},{"key":"10.1016\/j.slasd.2025.100230_bib0024","first-page":"89","article-title":"Design of small-molecule smac mimetics as IAP antagonists","volume":"348","author":"Wang","year":"2011","journal-title":"Curr Top Microbiol"},{"key":"10.1016\/j.slasd.2025.100230_bib0025","article-title":"Potency and selectivity of SMAC\/DIABLO mimetics in solid tumor therapy","volume":"9","author":"Zhao","year":"2020","journal-title":"Cells-Basel"},{"key":"10.1016\/j.slasd.2025.100230_bib0026","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.csbj.2019.01.009","article-title":"Targeting the BIR domains of inhibitor of apoptosis (IAP) proteins in cancer treatment","volume":"17","author":"Cossu","year":"2019","journal-title":"Comput Struct Biotec"},{"key":"10.1016\/j.slasd.2025.100230_bib0027","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1667\/RADE-20-00171.1","article-title":"SMAC Mimetic\/IAP inhibitor birinapant enhances radiosensitivity of glioblastoma multiforme","volume":"195","author":"Cerna","year":"2021","journal-title":"Radiat Res"},{"key":"10.1016\/j.slasd.2025.100230_bib0028","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1158\/1078-0432.CCR-14-3156","article-title":"Effect of a smac mimetic (TL32711, Birinapant) on the apoptotic program and apoptosis biomarkers examined with validated multiplex immunoassays fit for clinical use","volume":"22","author":"Srivastava","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.slasd.2025.100230_bib0029","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3389\/fphar.2018.01298","article-title":"The SMAC Mimetic APG-1387 sensitizes immune-mediated cell apoptosis in hepatocellular carcinoma","volume":"9","author":"Chen","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.slasd.2025.100230_bib0030","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13046-018-0774-7","article-title":"Correction to: novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, ripoptosome and autophagy mediated cell death pathway","volume":"37","author":"Li","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.slasd.2025.100230_bib0031","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.canlet.2016.07.008","article-title":"A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis","volume":"381","author":"Li","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.slasd.2025.100230_bib0032","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bcp.2018.04.020","article-title":"A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity","volume":"154","author":"Pan","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.slasd.2025.100230_bib0033","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ijc.2910450306","article-title":"Metallothionein gene expression and resistance to cisplatin in human ovarian cancer","volume":"45","author":"Schilder","year":"1990","journal-title":"Int J Cancer"},{"key":"10.1016\/j.slasd.2025.100230_bib0034","first-page":"4501","article-title":"Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma","volume":"47","author":"Hazelton","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.slasd.2025.100230_bib0035","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1535-7163.MCT-15-0074","article-title":"Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression","volume":"14","author":"Teicher","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.slasd.2025.100230_bib0036","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1177\/24725552211038362","article-title":"Complex tumor spheroids, a tissue-mimicking tumor model, for drug discovery and precision medicine","volume":"26","author":"Kaur","year":"2021","journal-title":"SLAS Discov"},{"key":"10.1016\/j.slasd.2025.100230_bib0037","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/2767-9764.CRC-23-0193","article-title":"Multicellular complex tumor spheroid response to DNA repair inhibitors in combination with DNA-damaging drugs","volume":"3","author":"Dexheimer","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.slasd.2025.100230_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.slasd.2024.100186","article-title":"Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor","volume":"29","author":"Dexheimer","year":"2024","journal-title":"SLAS Discov"},{"key":"10.1016\/j.slasd.2025.100230_bib0039","series-title":"HTS assay validation","author":"Iversen","year":"2004"},{"key":"10.1016\/j.slasd.2025.100230_bib0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.slasd.2025.100230_bib0041","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"key":"10.1016\/j.slasd.2025.100230_bib0042","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/1535-7163.MCT-23-0267","article-title":"Targeted investigational oncology agents in the NCI-60: a phenotypic systems-based resource","volume":"22","author":"Morris","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.slasd.2025.100230_bib0043","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/jnci\/81.14.1088","article-title":"Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm","volume":"81","author":"Paull","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.slasd.2025.100230_bib0044","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.4161\/cc.5.23.3520","article-title":"Concomitant inhibition of MDM2 and bcl-2 protein function synergistically induce mitochondrial apoptosis in AML","volume":"5","author":"Kojima","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.slasd.2025.100230_bib0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-016-0280-3","article-title":"Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models","volume":"9","author":"Lehmann","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.slasd.2025.100230_bib0046","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic lethality of combined bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.slasd.2025.100230_bib0047","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.2022016362","article-title":"Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial","volume":"141","author":"Daver","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.slasd.2025.100230_bib0048","doi-asserted-by":"crossref","first-page":"e701","DOI":"10.1097\/HS9.0000000000000701","article-title":"Targeting apoptosis pathways with BCL2 and MDM2 inhibitors in adult B-cell acute lymphoblastic leukemia","volume":"6","author":"Hohtari","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.slasd.2025.100230_bib0049","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1038\/s41375-023-02057-x","article-title":"Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia","volume":"37","author":"Johansson","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.slasd.2025.100230_bib0050","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41375-024-02241-7","article-title":"Combination p53 activation and BCL-x(L)\/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia","volume":"38","author":"Bell","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.slasd.2025.100230_bib0051","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2019.12.012","article-title":"Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2\/XL\/W and MDM2 as a potential therapy in uveal melanoma","volume":"126","author":"Decaudin","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.slasd.2025.100230_bib0052","doi-asserted-by":"crossref","first-page":"57047","DOI":"10.18632\/oncotarget.18982","article-title":"Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma","volume":"8","author":"Van Goethem","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.slasd.2025.100230_bib0053","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-152207","article-title":"Antitumor activity of dual BCL-2\/BCL-xl inhibitor pelcitoclax (APG-1252) in natural killer\/T-cell lymphoma (NK\/TCL)","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.slasd.2025.100230_bib0054","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw122","article-title":"Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression","volume":"108","author":"Polley","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.slasd.2025.100230_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102310","article-title":"Unmasking BCL-2 addiction in synovial sarcoma by overcoming low NOXA","volume":"13","author":"Fairchild","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.slasd.2025.100230_bib0056","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1158\/1541-7786.MCR-22-0588","article-title":"Interdependence of SS18-SSX-driven YAP1 and beta-catenin activation in Synovial Sarcoma","volume":"21","author":"Isfort","year":"2023","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.slasd.2025.100230_bib0057","doi-asserted-by":"crossref","first-page":"16581","DOI":"10.18632\/oncotarget.7667","article-title":"Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma","volume":"7","author":"Nakayama","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.slasd.2025.100230_bib0058","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-019-0803-9","article-title":"Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.slasd.2025.100230_bib0059","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33784-2","article-title":"Dual inhibition of bcl-2\/bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems","volume":"8","author":"Shang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.slasd.2025.100230_bib0060","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41419-019-1627-9","article-title":"XPO1 inhibitor KPT-330 synergizes with bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and mcl-1 protein synthesis","volume":"10","author":"Zhu","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.slasd.2025.100230_bib0061","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1158\/1078-0432.CCR-18-0277","article-title":"The Ewing Family of tumors relies on BCL-2 and BCL-X(L) to escape PARP inhibitor toxicity","volume":"25","author":"Heisey","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.slasd.2025.100230_bib0062","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41392-020-00358-6","article-title":"Development of synthetic lethality in cancer: molecular and cellular classification","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.slasd.2025.100230_bib0063","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.11542","article-title":"Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors","volume":"38","author":"Zhang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.slasd.2025.100230_bib0064","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e20612","article-title":"First-in-human study of pelcitoclax (APG-1252) in combination with paclitaxel in patients (pts) with relapsed\/refractory small-cell lung cancer (R\/R SCLC)","volume":"40","author":"Qin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.slasd.2025.100230_bib0065","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["SLAS Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555225000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555225000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:12:50Z","timestamp":1762629170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472555225000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":65,"alternative-id":["S2472555225000231"],"URL":"https:\/\/doi.org\/10.1016\/j.slasd.2025.100230","relation":{},"ISSN":["2472-5552"],"issn-type":[{"value":"2472-5552","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroids","name":"articletitle","label":"Article Title"},{"value":"SLAS Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.slasd.2025.100230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening.","name":"copyright","label":"Copyright"}],"article-number":"100230"}}